Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve-Reference-Cited by-同舟云学术

Biosimilars in the European Union from comparability exercise to real world experience: What we achieved and what we still need to achieve

Published:2017-05 Issue: Volume:119 Page:265-271
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Scavone Cristina,Sportiello Liberata,Berrino Liberato,Rossi Francesco,Capuano Annalisa

Publisher

Elsevier BV

Subject

Pharmacology

Reference63 articles.

1. History of insulin;Quianzon;J. Commun. Hosp. Intern. Med. Perspect.,2012

2. Defining the difference: what makes biologics unique;Morrow;Biotechnol. Healthc.,2004

3. Biopharmaceuticals from microorganisms: from production to purification;Jozala;Braz. J. Microbiol.,2016

4. Biosimilars: potential implications for clinicians;Eleryan;Clin. Cosmet. Investig. Dermatol.,2016

5. Pharmacoutilization of epoetins in naïve patients with hematological malignancies in an unselected Italian population under clinical practice setting: a comparative analysis between originator and biosimilars;Perrone;Biologics,2016

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Switching between Originators and Biosimilars in Dermatology: A Systematic Review of Real-World Clinical Studies;Biologics;2023-04-27

2. Preliminary Results of the FASM Study, an On-Going Italian Active Pharmacovigilance Project;Pharmaceuticals;2020-12-15

3. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database;Frontiers in Pharmacology;2020-06-09

4. Biosimilars vs originators: Are they the same?;Autoimmunity Reviews;2019-12

5. The New Paradigms in Clinical Research: From Early Access Programs to the Novel Therapeutic Approaches for Unmet Medical Needs;Frontiers in Pharmacology;2019-02-13